Validation of Clinical Testing for Warfarin Sensitivity: Comparison of CYP2C9-VKORC1 Genotyping Assays and Warfarin-Dosing Algorithms
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in The Journal of Molecular Diagnostics
- Vol. 11 (3), 216-225
- https://doi.org/10.2353/jmoldx.2009.080123
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions inVKORC1Journal of Thrombosis and Haemostasis, 2008
- Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patientsJournal of Thrombosis and Haemostasis, 2008
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humansJournal of Thrombosis and Haemostasis, 2008
- Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–AmericansPharmacogenomics, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinCancer Cell, 2008
- Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish PopulationsAmerican Journal of Human Genetics, 2008
- Genetic-based dosing in orthopedic patients beginning warfarin therapyBlood, 2007
- Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulationJournal of Medical Genetics, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005